1.	Phase III/IV Randomized Study of Risk-Adapted Therapy Comprising Observation Only, Combination Chemotherapy, Radiotherapy, and/or Autologous Stem Cell Transplantation in Younger Patients With Neuroblastoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase IV, Phase III Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: GPOH-NB2004, EU-20661, NCT00410631
2.	131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 1 to 14 Sponsor: Other Protocol IDs: 87-01-36-6853, NCT00798148
3.	Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma Phase: Phase II Type: Treatment Status: Active Age: Over 1 Sponsor: NCI, Other Protocol IDs: 04-148, MSKCC-04148, NCT00107289
4.	Iodobenzylguanidine Meta-I131 and Topotecan in Treating Young Patients With Refractory or Relapsed Metastatic Neuroblastoma Phase: Phase II Type: Treatment Status: Active Age: 1 to 20 Sponsor: Other Protocol IDs: CDR0000633586, COL-MIITOP, COL-2006-07, INCA-RECF0633, EUDRACT-2006-004862-15, MIITOP, NCT00960739
5.	N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 30 Sponsor: NCI, Other Protocol IDs: CDR0000659059, P01CA081403, N2007-03, NANT-N2007-03, NCT01019850
6.	Diagnosis of Pheochromocytoma Phase: No phase specified Type: Biomarker/Laboratory analysis, Diagnostic Status: Active Age: Not specified Sponsor: NICHD Protocol IDs: 000093, 00-CH-0093, NCT00004847
7.	Randomized Study of Standard Induction Chemotherapy Versus Topotecan Hydrochloride-Containing Induction Chemotherapy Followed by Myeloablative Autologous Stem Cell Transplantation and Consolidation Therapy With Isotretinoin in Pediatric Patients With High-Risk Neuroblastoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: No phase specified Type: Treatment Status: Active Age: 6 months to 21 Sponsor: Other Protocol IDs: GPOH-NB2004-HR, NB2004-HR, UNI-KOELN-161, NCT00526318, EU-20661
8.	Haploidentical Stem Cell Transplantation in Neuroblastoma Phase: No phase specified Type: Treatment Status: Active Age: 6 months to 21 years Sponsor: Other Protocol IDs: 385/2005, NCT00790413
9.	131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Pheochromocytoma Phase: No phase specified Type: Treatment Status: Active Age: 1 and over Sponsor: Other Protocol IDs: 2005-02-4159, NCT01163383
10.	Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 30 Sponsor: NCI, Other Protocol IDs: CDR0000682629, COG-ANBL09P1, ANBL09P1, NCT01175356
11.	High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma Phase: No phase specified Type: Treatment Status: Active Age: 1 to 30 Sponsor: Other Protocol IDs: MIBG Irino, NCT01313936
12.	131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol Phase: No phase specified Type: Treatment Status: Active Age: 1 and over Sponsor: Other Protocol IDs: CompUse MIBG, NCT01370330